Background: Gastrointestinal cancer As the main killer of cirrhotic patients, HCC is a major worldwide health problem, accounting for more than 5% of all malignancies. The selection of the most appropriate treatment option for (HCC) patients depends not only on tumor burden but also on liver function and the general performance status of patients. It has recently been demonstrated that (TACE) provides a survival benefit and become a standard treatment in selected patientsThe goal of this review was to talk about how TACE responds to tumours in people who have HCC that is Child Pugh Grade A. Results: Patients with Child-Pugh Grade A early-stage hepatocellular carcinoma who are unable to undergo surgery may benefit greatly from TACE, as shown by the study's 60% complete response rate. Importantly, the research found that a good prognosis after TACE is strongly predicted by a lower tumour size, the lack of an expanded belly, and ultrasonography homogeneity. In order to optimise patient selection and improve clinical results for HCC patients, it is crucial to consider tumour features and clinical presentation when predicting TACE outcomes. |
